Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease

NCT00400634 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
PROCEDURE: Sham Surgery

Sponsor

Sangamo Therapeutics

Collaborators

[object Object]